Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152678 | 0.88 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3HSPB1MAPT | |
| SCHEMBL6152042 | 0.84 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6151376 | 0.81 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL31009437 | 0.80 | HSPB1 (0.50) | HSPB1MAPTNPSR1MEN1ALDH1A1 | |
| SCHEMBL11856448 | 0.79 | HSPB1 (0.72) | HSPB1MAPTNPSR1MEN1ALDH1A1 | |
| SCHEMBL5836477 | 0.79 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6151567 | 0.79 | SLC6A4 (0.70) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6152604 | 0.78 | SLC6A4 (0.71) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL13242050 | 0.77 | ALDH1A1 (0.50) | HSPB1MAPTNPSR1MEN1ALDH1A1 | |
| SCHEMBL6946066 | 0.76 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268396-B1 | DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-6448293-B1 | TREATMENT OR PREVENTION OF A DISORDER IN WHICH THE REGULATION OF MONOAMINE TRANSPORTER FUNCTION IS IMPLICATED, SUCH AS PREMATURE EJACULATION. | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | ANDREWS MARK DAVID (GB) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | CBR1, OGFR, CBR3 | SLC6A4 2002/4885SLC6A2 1349/4885SLC6A3 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.